Technology | July 25, 2014

FDA Clears CorMatrix ECM for Vascular Repair

cormatrix, cardiovascular, cardiovascular repair

CorMatrix ECM for Vascular Repair


CorMatrix Cardiovascular announced that it has received U.S. Food and Drug Administration (FDA) clearance to market the CorMatrix ECM for Vascular Repair.
 
The CorMatrix ECM for Vascular Repair is intended for use as a patch material for repair and reconstruction of peripheral vasculature including the carotid, renal, iliac, femoral, and tibial blood vessels. The CorMatrix ECM for Vascular Repair may be used for patch closure of vessels, as a pledget, or for suture line buttressing when repairing peripheral vessels. It is constructed from a multi-laminate sheet of decellularized, non-crosslinked, lyophilized extracellular matrix (ECM) derived from porcine small intestinal submucosa (SIS).
 
According to Dr. Richard F. Neville, Professor of Surgery, Chief, Division of Vascular Surgery at George Washington University, “CorMatrix ECM for Vascular Repair is an innovative scaffold permitting the patient’s own stem cells to regenerate viable autogenous tissue improving the results of revascularization procedures that often fail due to myointimal hyperplasia and accelerated atherosclerosis.”
 
“The CorMatrix ECM for Vascular Repair is an expansion of the current indications for our CorMatrix ECM for Carotid Repair and was pursued due to requests by our physicians for a product that could be used to repair blood vessels throughout the vascular system. CorMatrix devices have now been used in over 100,000 patients worldwide to treat a growing number of cardiovascular indications. We are pleased that we can address these additional requests by physicians, providing a novel device to meet current clinical needs,” commented Andrew Green, CorMatrix Cardiovascular’s Executive Vice President of Operations. “Expansion of our current FDA-cleared devices to satisfy unmet indications further strengthens our leadership position in the field of ECM technologies and regenerative medicine, utilizing the patient’s own stem cells and their natural healing ability.”
 
For more information: www.cormatrix.com.

Related Content

News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
News | Cardiovascular Surgery

December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...

Home December 20, 2023
Home
News | Cardiovascular Surgery

December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...

Home December 18, 2023
Home
News | Cardiovascular Surgery

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
News | Cardiovascular Surgery

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

Home October 25, 2023
Home
News | Cardiovascular Surgery

October 18, 2023 — A study published in The Annals of Thoracic Surgery demonstrates outstanding long-term survival ...

Home October 18, 2023
Home
Subscribe Now